Facebook Linkedin Twitter
Inside Precision Medicine Lilly Pays up to $2.5B for Selective PI3Kα Inhibitor  

Cancer drug discovery

woman lymph armpit examination. Node-Positive Breast Cancer
News & Features

Lilly Pays up to $2.5B for Selective PI3Kα Inhibitor  

0
drug modifying concept
Informatics

How Is Artificial Intelligence Changing the Clinical Trials Landscape?

Larissa Warneck-Silvestrin
0
cancer development
News & Features

Genialis Uses Machine Learning to Personalize Cancer Treatment Outcomes 

Jonathan D. Grinstein, PhD
0
Skin cancer, light micrograph
News & Features

MEK Inhibitor Sparks Hope as Novel Treatment for Common Skin Cancer

0
T Cells Attacking Cancer Cell
News & Features

Time of Day May Be Important for Cancer Diagnosis and Treatment

Laura Cowen
0
Destruction of leukaemia cell in blood cancer
News & Features

Promising Menin Inhibitor Results from Leukemia Trial Published

0
For Blood and Money book cover
Book Reviews

For Blood and Money

0
Cancer Cells under microscope
News & Features

Novel Approach Detects Targets in Heterogenous Cancers

0
Scorpion Therapeutics, AstraZeneca Ink Deal Focused on “Undruggable” Cancer Targets.
News & Features

Scorpion Therapeutics, AstraZeneca Ink Deal Focused on “Undruggable” Cancer Targets.

0
Triple negative breast cancer cell undergoing retraction and apoptosis
News & Features

Triple Negative Breast Cancer’s Newest Target: MAPK4

0
12Page 1 of 2

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine